Eddingpharm (Cayman) Inc. to Distribute Breast Cancer Drug for GlaxoSmithKline in China

Published: Apr 09, 2013

by Richard Daverman, PhD

April 8, 2013 -- Eddingpharm, a Shanghai company, signed a collaboration agreement with GlaxoSmithKline China that gives Eddingpharm exclusive rights to market and distribute Tykerb in China. Tykerb was recently approved by the SFDA as a treatment for patients with HER2 positive breast cancer. The drug was indicated as a second-line treatment in patients with advanced or metastatic cancer. Terms were not disclosed. More details....

Stock Symbol: (NYSE: GSK)

Back to news